US › Healthcare

Innate Pharma (IPHA)

US · Healthcare · Biotechnology

$1.44+2.86%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$3.2M

Revenue YoY

+1043.8%

Net profit

$-19.9M

EPS estimate

$-0.09

Net margin

-630.0%

Key statistics

Market cap

$156.4M

Forward P/E

0.0

P/B

20.10

Book value

$-0.49

EPS (TTM)

$-0.58

52-week high

$2.71

52-week low

$1.17

50-day MA

$1.71

200-day MA

$1.71

Beta

1.22

Analyst view

Analysts rate Innate Pharma a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $6.67.

Shareholding

Insiders

1.40%

Institutions

0.35%

Largest institutional holders

Fund	Stake
Lion Point Capital, LP	0.07%
Morgan Stanley - Brokerage Accounts	0.04%
SmartHarvest Portfolios, LLC	0.02%
XTX Topco Ltd	0.01%
Citadel Advisors Llc	0.01%
Jane Street Group LLC	0.01%
Rhumbline Advisers	0.00%
UBS Group AG	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Innate Pharma — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.